January 2012 Archives : Discussions About IMF Web Site Content
- What is Smoldering Myeloma?
- FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
- ASH 2011 Highlights
- Special Myeloma Minute on FDA Approved Data for VELCADE
- First Teleconference of 2012
Best of ASH 2011 ? What Patients Need to Know - Advocacy Update - January 16, 2012
- Rational Design of Heparanase Inhibiting Compounds and Antibodies for the Treatment of Multiple Myeloma
- GSK3beta Inhibition Reduces the Effects of Multiple Myeloma Induced Bone Disease
- Targeting UBC13-UEV1A for Treatment of Multiple Myeloma
- Investigating the role of NAD+ and NAD+-dependent enzymes in Multiple Myeloma
- FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
- ASH 2011 Highlights
- Special Myeloma Minute on FDA Approved Data for VELCADE
- Advocacy Update - January 16, 2012
- What is Smoldering Myeloma?
- First Teleconference of 2012
Best of ASH 2011 ? What Patients Need to Know - Rational Design of Heparanase Inhibiting Compounds and Antibodies for the Treatment of Multiple Myeloma
- GSK3beta Inhibition Reduces the Effects of Multiple Myeloma Induced Bone Disease
- Targeting UBC13-UEV1A for Treatment of Multiple Myeloma
- Investigating the role of NAD+ and NAD+-dependent enzymes in Multiple Myeloma